SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 – - Reported Positive Phase 2...
13 days ago